BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics - Gilde Healthcare

BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics

3 March 2009

Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics.  In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s commercial operations as it advances a broad portfolio of high-value diagnostic tests toward commercial launch.

Mr. White brings more than 24 years of successful experience in the in vitro diagnostic marketplace to BG Medicine, including roles at innovative leading companies such as QIAGEN, Digene, Bayer, Chiron Diagnostics, and Abbott Diagnostics.  Prior to joining BGM, Mr. White served as QIAGEN’s Sr. Vice President of Sales and Marketing for the Americas, and Chair of the Americas Management Council, where among other responsibilities he played a critical role in the successful integration of Digene Corporation following its acquisition.  Mr. White also served as Senior Vice President of Commercial Operations, leading commercial activities in the Americas and Asia Pacific and heading the company’s global product management organization at Digene.

“Doug’s vast experience with leading diagnostics innovators will be a tremendous asset to BG Medicine as we prepare to commercialize important new diagnostics in cardiology and other therapeutic areas,”

said BG Medicine President and CEO Pieter Muntendam.

“The success that Doug achieved in a variety of commercial leadership roles has prepared him well to help BG Medicine effectively develop and penetrate these large, important markets.”

“I am very excited to join BG Medicine at such a critical juncture, as we turn our biomarker discovery abilities into groundbreaking new diagnostic tests,” Mr. White said. “BG Medicine is poised to have a major impact on the improvement in patient care and management of a wide array of diseases, beginning with cardiology.”

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins, and metabolites collected from bodily fluids.

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
4 October 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
29 September 2021